Jason M. Greene

Array ( [id] => 20722245 [patent_doc_number] => 20260138948 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-05-21 [patent_title] => N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 19/446246 [patent_app_country] => US [patent_app_date] => 2026-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30990 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19446246 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20562901 [patent_doc_number] => 12565502 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-03 [patent_title] => Substituted 1',2'-dihydro-3'h-spiro[cyclohexane-1,4'-pyrimido[5',4':4,5]pyrrolo[2,1-c] [1,2,4]triazin]-3'-ones as cyclin-dependent kinase inhibitors [patent_app_type] => utility [patent_app_number] => 19/205807 [patent_app_country] => US [patent_app_date] => 2025-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43662 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19205807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20136140 [patent_doc_number] => 20250243184 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-31 [patent_title] => COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS [patent_app_type] => utility [patent_app_number] => 19/072824 [patent_app_country] => US [patent_app_date] => 2025-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56767 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19072824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20007382 [patent_doc_number] => 20250145604 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-08 [patent_title] => COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS [patent_app_type] => utility [patent_app_number] => 19/016827 [patent_app_country] => US [patent_app_date] => 2025-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43921 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19016827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20040871 [patent_doc_number] => 20250179093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-05 [patent_title] => KRAS MODULATORS [patent_app_type] => utility [patent_app_number] => 19/015403 [patent_app_country] => US [patent_app_date] => 2025-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 148234 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19015403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19768364 [patent_doc_number] => 20250049790 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-13 [patent_title] => TREATMENT OF NEUROLOGICAL DISORDERS [patent_app_type] => utility [patent_app_number] => 18/927377 [patent_app_country] => US [patent_app_date] => 2024-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32293 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18927377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19528135 [patent_doc_number] => 20240352037 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS [patent_app_type] => utility [patent_app_number] => 18/745209 [patent_app_country] => US [patent_app_date] => 2024-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60643 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 240 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18745209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19497602 [patent_doc_number] => 20240336620 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-10 [patent_title] => PROTEIN DEGRADATION COMPOUNDS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/744538 [patent_app_country] => US [patent_app_date] => 2024-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31969 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 259 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18744538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20213553 [patent_doc_number] => 12410195 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-09 [patent_title] => Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders [patent_app_type] => utility [patent_app_number] => 18/741739 [patent_app_country] => US [patent_app_date] => 2024-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7475 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18741739 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19631098 [patent_doc_number] => 20240409547 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-12 [patent_title] => Solid Forms of Upadacitinib [patent_app_type] => utility [patent_app_number] => 18/737389 [patent_app_country] => US [patent_app_date] => 2024-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10046 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18737389 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19683917 [patent_doc_number] => 20250002462 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-02 [patent_title] => SULFONE METHOD OF PREPARING PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS [patent_app_type] => utility [patent_app_number] => 18/676126 [patent_app_country] => US [patent_app_date] => 2024-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7997 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18676126 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19479393 [patent_doc_number] => 20240327435 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-03 [patent_title] => AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS [patent_app_type] => utility [patent_app_number] => 18/665844 [patent_app_country] => US [patent_app_date] => 2024-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68712 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18665844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19642878 [patent_doc_number] => 20240417398 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-19 [patent_title] => TETRAHYDRONAPTHYRIDINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD [patent_app_type] => utility [patent_app_number] => 18/666100 [patent_app_country] => US [patent_app_date] => 2024-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57005 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18666100 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19631104 [patent_doc_number] => 20240409553 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-12 [patent_title] => HETEROCYCLIC NLRP3 INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/665390 [patent_app_country] => US [patent_app_date] => 2024-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18665390 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19785513 [patent_doc_number] => 20250059192 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-20 [patent_title] => SUBSTITUTED IMIDAZOLES AS GLP-1 RECEPTOR AGONISTS [patent_app_type] => utility [patent_app_number] => 18/663450 [patent_app_country] => US [patent_app_date] => 2024-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63722 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18663450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19570461 [patent_doc_number] => 20240374753 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => USE OF AN AGONIST OF FORMYL PEPTIDE RECEPTORS 1 AND 2 FOR TREATING OCULAR INFLAMMATORY DISEASES [patent_app_type] => utility [patent_app_number] => 18/661074 [patent_app_country] => US [patent_app_date] => 2024-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7569 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18661074 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19624081 [patent_doc_number] => 12162885 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-10 [patent_title] => Crystal form of Xevinapant for treating LA SCCHN [patent_app_type] => utility [patent_app_number] => 18/658960 [patent_app_country] => US [patent_app_date] => 2024-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 7140 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18658960 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20240933 [patent_doc_number] => 12421241 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-23 [patent_title] => Substituted pyridines as PARP1 inhibitors [patent_app_type] => utility [patent_app_number] => 18/653538 [patent_app_country] => US [patent_app_date] => 2024-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28063 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18653538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19613155 [patent_doc_number] => 20240398835 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-05 [patent_title] => METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION [patent_app_type] => utility [patent_app_number] => 18/651458 [patent_app_country] => US [patent_app_date] => 2024-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7472 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18651458 [rel_patent_id] =>[rel_patent_doc_number] =>)